A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia

Abstract Background Hetrombopag, a novel thrombopoietin receptor agonist, has been found in phase I studies to increase platelet counts and reduce bleeding risks in adults with immune thrombocytopenia (ITP). This phase III study aimed to evaluate the efficacy and safety of hetrombopag in ITP patient...

Full description

Bibliographic Details
Main Authors: Heng Mei, Xiaofan Liu, Yan Li, Hu Zhou, Ying Feng, Guangxun Gao, Peng Cheng, Ruibin Huang, Linhua Yang, Jianda Hu, Ming Hou, Yazhou Yao, Li Liu, Yi Wang, Depei Wu, Liansheng Zhang, Changcheng Zheng, Xuliang Shen, Qi Hu, Jing Liu, Jie Jin, Jianmin Luo, Yun Zeng, Sujun Gao, Xiaohui Zhang, Xin Zhou, Qingzhi Shi, Ruixiang Xia, Xiaobao Xie, Zhongxing Jiang, Li Gao, Yuansong Bai, Junye Xiong, Runzi Li, Jianjun Zou, Ting Niu, Renchi Yang, Yu Hu
Format: Article
Language:English
Published: BMC 2021-02-01
Series:Journal of Hematology & Oncology
Subjects:
Immune thrombocytopenia
Hetrombopag
Thrombopoietin receptor agonists
Platelet response
Online Access:https://doi.org/10.1186/s13045-021-01047-9

Internet

https://doi.org/10.1186/s13045-021-01047-9

Similar Items